Year Founded
2002
Ownership
Private
Employees
~50
Therapeutic Areas
Immunology
Stage
Preclinical
Modalities
Protein therapeutics

ProThera Biologics General Information

Developing Inter-alpha inhibitor proteins (IAIP) therapy for acute inflammatory conditions. Currently in IND-enabling activities with Takeda.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

Novel Plasma-Derived IAIP Therapy
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to ProThera Biologics's pipeline data

Book a demo

Key Partnerships

Takeda Pharmaceutical Company

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

ProThera Biologics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view ProThera Biologics's complete valuation and funding history, request access »

ProThera Biologics Investors

Slater Technology Fund
Investor Type: Venture Capital
Holding: Minority
R.I. Commerce Corp.
Investor Type: Venture Capital
Holding: Minority